BITS

BITS Biopharma is a South Korean biotechnology company specializing in the discovery and development of small molecule therapeutics targeting protein-protein interactions (PPIs). The company utilizes its proprietary Bio-Information and Technology Solutions (BITS) platform, which integrates computational chemistry and structural biology to identify novel binding sites on challenging targets. Their primary focus is on oncology, with a pipeline featuring inhibitors for the Bcl-2 family of proteins, including Mcl-1 and Bcl-xL. By leveraging their platform, BITS Biopharma aims to develop next-generation precision medicines for various cancers and immunological disorders. The company's approach focuses on "undruggable" targets by identifying cryptic pockets in protein-protein interaction interfaces. BITS Biopharma is headquartered in Daejeon, South Korea, and has secured significant venture capital funding to advance its early-stage programs.